Why the study?
Do direct oral anticoagulants improve efficacy and safety in patients with atrial fibrillation and comorbid heart failure?
Do direct oral anticoagulants improve efficacy and safety in patients with atrial fibrillation and comorbid heart failure?
Answers are grounded in this paper and cite their sources.
This review summarizes evidence on the efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and comorbid heart failure to guide optimal anticoagulation decisions.
The recent epidemiological data presented, on the prevalence, incidence of atrial fibrillation and comorbid heart failure. The main evidence provided on the risk increase for thromboembolic complications in this category of patients, efficacy data provided, as safety, of the direct oral anticoagulants in atrial fibrillation patients with heart failure, that might facilitate decisions on optimal anticoagulation for this category of patients.
No takes yet. Share an insight, caveat, or question.
Tatarsky et al. (2017) conducted a review in Atrial fibrillation and heart failure. Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Stroke and systemic embolic complications (HR 0.86, 95% CI 0.76-0.98).
Synapse has enriched 10 related papers. Consider them for comparative context: